Clinical Trials Browser

Phase 2 × Recurrent Squamous Cell Lung Carcinoma × Immunoglobulin G × Clear all

NCT03373760 2023-06-09

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Phase 2 Completed

67 enrolled 17 charts

Recurrent Squamous Cell Lung Carcinoma